Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases

@article{Kostapanos2014BenefitRiskAO,
  title={Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases},
  author={Michael S. Kostapanos and Christos V Rizos and Moses S Elisaf},
  journal={Drug Safety},
  year={2014},
  volume={37},
  pages={481-500}
}
Rosuvastatin has been marketed for approximately a decade. In this review we critically discuss available evidence on the benefits and risks from its use. In clinical trials using rosuvastatin, ‘lowest is best’ was relevant for on-treatment low-density lipoprotein cholesterol levels. Targeting levels <50 mg/dl was associated with the greatest decrease in vascular morbidity/mortality in the primary prevention setting. Also, such reduction can induce atherosclerosis regression without increasing… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 177 REFERENCES

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study.

  • Hepatology research : the official journal of the Japan Society of Hepatology
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL